Redhawk Wealth Advisors Inc. Makes New Investment in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Redhawk Wealth Advisors Inc. purchased a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the fourth quarter, Holdings Channel reports. The fund purchased 52,416 shares of the company’s stock, valued at approximately $1,155,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Stifel Financial Corp raised its holdings in Teva Pharmaceutical Industries by 54.0% in the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock valued at $1,196,000 after buying an additional 23,283 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in shares of Teva Pharmaceutical Industries by 21.8% during the third quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock valued at $4,046,000 after acquiring an additional 40,218 shares during the last quarter. Sio Capital Management LLC bought a new stake in shares of Teva Pharmaceutical Industries in the third quarter worth $24,314,000. CWA Asset Management Group LLC acquired a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at $3,340,000. Finally, Two Sigma Advisers LP raised its position in Teva Pharmaceutical Industries by 15.3% during the 3rd quarter. Two Sigma Advisers LP now owns 1,034,500 shares of the company’s stock worth $18,642,000 after purchasing an additional 137,000 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Barclays upped their price target on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a research report on Wednesday, December 18th. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.88.

Teva Pharmaceutical Industries Trading Up 4.4 %

Shares of TEVA stock opened at $21.90 on Thursday. The firm has a 50 day moving average of $19.06 and a 200-day moving average of $18.14. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries Limited has a 52 week low of $10.83 and a 52 week high of $22.80.

Insiders Place Their Bets

In related news, EVP Christine Fox sold 19,388 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at $744,034.48. This trade represents a 30.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.